Let’s do something life-changing together

<!doctype html>   <html class="no-js no-svg" dir="ltr" lang="en-GB" prefix="og: https://ogp.me/ns#">  <head> <meta charset="UTF-8" /> <meta name="description" content="A quality and innovation-led CDMO in cell and gene therapy"> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <script type="text/javascript"> /* <![CDATA[ */ var gform;gform||(document.addEventListener("gform_main_scripts_loaded",function(){gform.scriptsLoaded=!0}),window.addEventListener("DOMContentLoaded",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,initializeOnLoaded:function(o){gform.domLoaded&&gform.scriptsLoaded?o():!gform.domLoaded&&gform.scriptsLoaded?window.addEventListener("DOMContentLoaded",o):document.addEventListener("gform_main_scripts_loaded",o)},hooks:{action:{},filter:{}},addAction:function(o,n,r,t){gform.addHook("action",o,n,r,t)},addFilter:function(o,n,r,t){gform.addHook("filter",o,n,r,t)},doAction:function(o){gform.doHook("action",o,arguments)},applyFilters:function(o){return gform.doHook("filter",o,arguments)},removeAction:function(o,n){gform.removeHook("action",o,n)},removeFilter:function(o,n,r){gform.removeHook("filter",o,n,r)},addHook:function(o,n,r,t,i){null==gform.hooks[o][n]&&(gform.hooks[o][n]=[]);var e=gform.hooks[o][n];null==i&&(i=n+"_"+e.length),gform.hooks[o][n].push({tag:i,callable:r,priority:t=null==t?10:t})},doHook:function(n,o,r){var t;if(r=Array.prototype.slice.call(r,1),null!=gform.hooks[n][o]&&((o=gform.hooks[n][o]).sort(function(o,n){return o.priority-n.priority}),o.forEach(function(o){"function"!=typeof(t=o.callable)&&(t=window[t]),"action"==n?t.apply(null,r):r[0]=t.apply(null,r)})),"filter"==n)return r[0]},removeHook:function(o,n,t,i){var r;null!=gform.hooks[o][n]&&(r=(r=gform.hooks[o][n]).filter(function(o,n,r){return!!(null!=i&&i!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][n]=r)}}); /* ]]> */ </script> <meta name="viewport" content="width=device-width, initial-scale=1"> <link rel="author" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/humans.txt" /> <link rel="pingback" href="https://oxb.com/xmlrpc.php" /> <link rel="profile" href="http://gmpg.org/xfn/11">  <link rel="apple-touch-icon" sizes="180x180" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/favicon-16x16.png"> <link rel="manifest" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/site.webmanifest"> <link rel="mask-icon" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/safari-pinned-tab.svg" color="#0071ce"> <link rel="shortcut icon" href="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/favicon.ico"> <meta name="apple-mobile-web-app-title" content="Oxford Biomedica"> <meta name="application-name" content="Oxford Biomedica"> <meta name="msapplication-TileColor" content="#0071ce"> <meta name="msapplication-config" content="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/src/img/favicons/browserconfig.xml"> <meta name="theme-color" content="#0071ce">  <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Raleway:ital,wght@0,400;0,700;1,400;1,700&display=swap" rel="stylesheet">  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5HMFVZW');</script>   <script async src="https://www.googletagmanager.com/gtag/js?id=G-FCQYC8TBF8"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-FCQYC8TBF8'); </script> <title>Let’s do something life-changing together</title>  <meta name="description" content="25+ years enabling the world’s most progressive and successful viral vector therapies. Full service offering, supported by robust quality systems." /> <meta name="robots" content="max-image-preview:large" /> <link rel="canonical" href="https://oxb.com/" /> <meta name="generator" content="All in One SEO (AIOSEO) 4.7.1.1" /> <meta property="og:locale" content="en_GB" /> <meta property="og:site_name" content="OXB - A quality and innovation-led CDMO in cell and gene therapy" /> <meta property="og:type" content="website" /> <meta property="og:title" content="Let’s do something life-changing together" /> <meta property="og:description" content="25+ years enabling the world’s most progressive and successful viral vector therapies. Full service offering, supported by robust quality systems." /> <meta property="og:url" content="https://oxb.com/" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:title" content="Let’s do something life-changing together" /> <meta name="twitter:description" content="25+ years enabling the world’s most progressive and successful viral vector therapies. Full service offering, supported by robust quality systems." /> <script type="application/ld+json" class="aioseo-schema"> {"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/oxb.com\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/oxb.com\/#listItem","position":1,"name":"Home"}]},{"@type":"Organization","@id":"https:\/\/oxb.com\/#organization","name":"Oxford Biomedica PLC","description":"A quality and innovation-led CDMO in cell and gene therapy","url":"https:\/\/oxb.com\/","telephone":"+441865783000","logo":{"@type":"ImageObject","url":"https:\/\/oxb.com\/wp-content\/uploads\/2024\/10\/OXB-Logo_Navy_RGB-1.png","@id":"https:\/\/oxb.com\/#organizationLogo","width":3000,"height":1588,"caption":"OXB-Logo"},"image":{"@id":"https:\/\/oxb.com\/#organizationLogo"}},{"@type":"WebPage","@id":"https:\/\/oxb.com\/#webpage","url":"https:\/\/oxb.com\/","name":"Let\u2019s do something life-changing together","description":"25+ years enabling the world\u2019s most progressive and successful viral vector therapies. Full service offering, supported by robust quality systems.","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/oxb.com\/#website"},"breadcrumb":{"@id":"https:\/\/oxb.com\/#breadcrumblist"},"datePublished":"2022-10-12T14:53:28+01:00","dateModified":"2024-11-26T18:42:02+00:00"},{"@type":"WebSite","@id":"https:\/\/oxb.com\/#website","url":"https:\/\/oxb.com\/","name":"Oxford Biomedica PLC","alternateName":"OXB","description":"A quality and innovation-led CDMO in cell and gene therapy","inLanguage":"en-GB","publisher":{"@id":"https:\/\/oxb.com\/#organization"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxb.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}}]} </script>  <link rel='dns-prefetch' href='//www.googletagmanager.com' /> <link rel="alternate" type="application/rss+xml" title="OXB » Feed" href="https://oxb.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="OXB » Comments Feed" href="https://oxb.com/comments/feed/" />     <style id='classic-theme-styles-inline-css' type='text/css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css' type='text/css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='main-css' href='https://oxb.com/wp-content/themes/oxfordbiomedica-wp/dist/css/theme.min.css?ver=202411262353' type='text/css' media='all' /> <link rel='stylesheet' id='styles-css' href='https://oxb.com/wp-content/themes/oxfordbiomedica-wp/style.css?ver=6.6.2' type='text/css' media='all' />   <script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=GT-WF35X9NZ" id="google_gtagjs-js" async></script> <script type="text/javascript" id="google_gtagjs-js-after"> /* <![CDATA[ */ window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} gtag("set","linker",{"domains":["oxb.com"]}); gtag("js", new Date()); gtag("set", "developer_id.dZTNiMT", true); gtag("config", "GT-WF35X9NZ"); /* ]]> */ </script>  <link rel="https://api.w.org/" href="https://oxb.com/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://oxb.com/wp-json/wp/v2/pages/2" /><link rel='shortlink' href='https://oxb.com/' /> <link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://oxb.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Foxb.com%2F" /> <link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://oxb.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Foxb.com%2F&format=xml" /> <meta name="generator" content="Site Kit by Google 1.140.0" />  <script type="text/javascript"> /* <![CDATA[ */ ( function( w, d, s, l, i ) { w[l] = w[l] || []; w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} ); var f = d.getElementsByTagName( s )[0], j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore( j, f ); } )( window, document, 'script', 'dataLayer', 'GTM-KBH23HR8' ); /* ]]> */ </script>  </head> <body onload="document.body.className += ' loaded';" class="home page-template page-template-page-templates page-template-template-flex page-template-page-templatestemplate-flex-php page page-id-2" data-template="base.twig">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5HMFVZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="page-wrapper relative"> <nav class="mobile-nav" id="mobile-nav"> <div class="header"> <ul> <li class="search"> <form role="search" method="get" class="searchform" action="/"> <div> <input type="text" value="" placeholder="Keyword search..." name="s" /> <button aria-label="Search" type="submit"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path d="M416 208c0 45.9-14.9 88.3-40 122.7L502.6 457.4c12.5 12.5 12.5 32.8 0 45.3s-32.8 12.5-45.3 0L330.7 376c-34.4 25.2-76.8 40-122.7 40C93.1 416 0 322.9 0 208S93.1 0 208 0S416 93.1 416 208zM208 352c79.5 0 144-64.5 144-144s-64.5-144-144-144S64 128.5 64 208s64.5 144 144 144z"/></svg></button> </div> </form> </li> <li class="burger"> <button id="burger2" class="is-open"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path d="M310.6 150.6c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L160 210.7 54.6 105.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L114.7 256 9.4 361.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 301.3 265.4 406.6c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3L205.3 256 310.6 150.6z"/></svg>Menu</button> </li> </ul> </div> <div class="menu-items" data-simplebar> <ul> <li class="accordion"> <div class="main-link"> <a href="#" title="About us link"> About us </a> <button data-action="accordion" data-target="About us" class="accordion__toggle"><svg xmle2ns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"><path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"></path></svg>Expand menu</button> </div> <div data-item="About us" class="accordion__panel z-400"> <ul class="accordion__inner"> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="/about/" title=""> Overview </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/about/our-people/" title=""> Our People </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/events/" title=""> Events </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/our-facilities/" title=""> Our Facilities </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/news/" title=""> News </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/about/sustainability/" title=""> Sustainability </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/about/sustainability/integrity-and-ethics/" title=""> Integrity and Ethics </a> </li> </ul> </div> </li> <li class="accordion"> <div class="main-link"> <a href="/services/" title="Our Services link"> Our Services </a> <button data-action="accordion" data-target="Our Services" class="accordion__toggle"><svg xmle2ns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"><path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"></path></svg>Expand menu</button> </div> <div data-item="Our Services" class="accordion__panel z-400"> <ul class="accordion__inner"> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/services/" title=""> Overview </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/services/analytics/" title=""> Analytics </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/services/process-development/" title=""> Process Development </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/services/quality-and-regulatory/" title=""> Quality and Regulatory </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/services/manufacturing/" title=""> Manufacturing </a> </li> </ul> </div> </li> <li class="accordion"> <div class="main-link"> <a href="#" title="Viral Vectors link"> Viral Vectors </a> <button data-action="accordion" data-target="Viral Vectors" class="accordion__toggle"><svg xmle2ns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"><path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"></path></svg>Expand menu</button> </div> <div data-item="Viral Vectors" class="accordion__panel z-400"> <ul class="accordion__inner"> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/lentivector/" title=""> LentiVector® platform </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/adeno-associated-virus-aav/" title=""> inAAVate™ platform </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/other-vectors/" title=""> Other Viral Vectors </a> </li> </ul> </div> </li> <li > <div class="main-link"> <a href="https://oxb.com/knowledge-centre/" title="Knowledge Centre link"> Knowledge Centre </a> </div> </li> <li > <div class="main-link"> <a href="https://careers.oxb.com/" title="Careers link"> Careers </a> </div> </li> <li class="accordion"> <div class="main-link"> <a href="#" title="Investors link"> Investors </a> <button data-action="accordion" data-target="Investors" class="accordion__toggle"><svg xmle2ns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"><path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"></path></svg>Expand menu</button> </div> <div data-item="Investors" class="accordion__panel z-400"> <ul class="accordion__inner"> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="/information#analyst-coverage" title=""> Analyst coverage </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="/information/#registrars" title=""> Registrars </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="/information#investor-contacts" title=""> Investor contacts </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/share-price-information/" title=""> Share Price Information </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/results-reports-presentations-webcasts/" title=""> Results, Reports, Presentations & Webcasts </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/regulatory-news/" title=""> Regulatory News </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/shareholder-meetings/" title=""> Shareholder Meetings, Circulars & Prospectuses </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/regulatory-news/acquisition-of-oxb-france/" title=""> Acquisition of ABL Europe (Oxford Biomedica France SAS) </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/corporate-governance/" title=""> Corporate Governance </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/board-committees/" title=""> Board Committees </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/french-subsidiary/" title=""> Subsidiaries governance & compliance </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/warning-shareholders/" title=""> Warning to Shareholders </a> </li> <li> <a class="sub-menu__top-link block text-white text-no-underline" href="https://oxb.com/investor-events/" title=""> Investor Calendar </a> </li> </ul> </div> </li> <li > <div class="main-link"> <a href="https://oxb.com/contact/" title="Get In Touch link"> Get In Touch </a> </div> </li> </ul> </div> </nav> <header class="site-header"> <div class="wrapper flex flex--wrap flex--align-stretch flex--justify-space-between">  <figure class="site-header__logo" style="padding-left: 2rem;"> <a href="https://oxb.com" title="Visit Homepage"> <img src="https://oxb.com/wp-content/uploads/2024/09/OXB-Logo.svg" width="122" height="63" alt="OXB"> </a> </figure> <nav class="site-header__nav"> <ul class="flex flex--wrap m-none p-none list-unstyled"> <li class="has-sub-menu relative"> <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="#" target="" title="About us link"> About us <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"> <path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"/> </svg> <span class="wrap"><span></span></span> </a> <ul class="sub-menu hidden absolute bg-off-black z-400"> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="/about/" title=""> Overview </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/about/our-people/" title=""> Our People </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/events/" title=""> Events </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/our-facilities/" title=""> Our Facilities </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/news/" title=""> News </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/about/sustainability/" title=""> Sustainability </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/about/sustainability/integrity-and-ethics/" title=""> Integrity and Ethics </a> </li> </ul> </li> <li class="has-sub-menu relative"> <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="/services/" target="" title="Our Services link"> Our Services <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"> <path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"/> </svg> <span class="wrap"><span></span></span> </a> <ul class="sub-menu hidden absolute bg-off-black z-400"> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/services/" title=""> Overview </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/services/analytics/" title=""> Analytics </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/services/process-development/" title=""> Process Development </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/services/quality-and-regulatory/" title=""> Quality and Regulatory </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/services/manufacturing/" title=""> Manufacturing </a> </li> </ul> </li> <li class="has-sub-menu relative"> <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="#" target="" title="Viral Vectors link"> Viral Vectors <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"> <path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"/> </svg> <span class="wrap"><span></span></span> </a> <ul class="sub-menu hidden absolute bg-off-black z-400"> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/lentivector/" title=""> LentiVector® platform </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/adeno-associated-virus-aav/" title=""> inAAVate™ platform </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/other-vectors/" title=""> Other Viral Vectors </a> </li> </ul> </li> <li > <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="https://oxb.com/knowledge-centre/" target="" title="Knowledge Centre link"> Knowledge Centre <span class="wrap"><span></span></span> </a> </li> <li > <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="https://careers.oxb.com/" target="" title="Careers link"> Careers <span class="wrap"><span></span></span> </a> </li> <li class="has-sub-menu relative"> <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="#" target="" title="Investors link"> Investors <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" fill="var(--off-black)" height="1rem"> <path d="M224 416c-8.188 0-16.38-3.125-22.62-9.375l-192-192c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0L224 338.8l169.4-169.4c12.5-12.5 32.75-12.5 45.25 0s12.5 32.75 0 45.25l-192 192C240.4 412.9 232.2 416 224 416z"/> </svg> <span class="wrap"><span></span></span> </a> <ul class="sub-menu hidden absolute bg-off-black z-400"> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="/information#analyst-coverage" title=""> Analyst coverage </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="/information/#registrars" title=""> Registrars </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="/information#investor-contacts" title=""> Investor contacts </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/share-price-information/" title=""> Share Price Information </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/results-reports-presentations-webcasts/" title=""> Results, Reports, Presentations & Webcasts </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/regulatory-news/" title=""> Regulatory News </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/shareholder-meetings/" title=""> Shareholder Meetings, Circulars & Prospectuses </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/regulatory-news/acquisition-of-oxb-france/" title=""> Acquisition of ABL Europe (Oxford Biomedica France SAS) </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/corporate-governance/" title=""> Corporate Governance </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/board-committees/" title=""> Board Committees </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/french-subsidiary/" title=""> Subsidiaries governance & compliance </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/warning-shareholders/" title=""> Warning to Shareholders </a> </li> <li> <a class="sub-menu__tier_1 block text-white hover-bg-black text-no-underline" href="https://oxb.com/investor-events/" title=""> Investor Calendar </a> </li> </ul> </li> <li > <a class="flex flex--align-center relative text-white hover-text-red font-medium text-no-underline text-uppercase" href="https://oxb.com/contact/" target="" title="Get In Touch link"> Get In Touch <span class="wrap"><span></span></span> </a> </li> </ul> </nav> <div class="site-header__icon"> <ul> <li class="burger"> <button id="burger"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path d="M0 96C0 78.3 14.3 64 32 64H416c17.7 0 32 14.3 32 32s-14.3 32-32 32H32C14.3 128 0 113.7 0 96zM0 256c0-17.7 14.3-32 32-32H416c17.7 0 32 14.3 32 32s-14.3 32-32 32H32c-17.7 0-32-14.3-32-32zM448 416c0 17.7-14.3 32-32 32H32c-17.7 0-32-14.3-32-32s14.3-32 32-32H416c17.7 0 32 14.3 32 32z"/></svg>Menu</button> </li> </ul> </div> </div> </header> <main role="main"> <section class="module module-banner text-light bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div id="launch-banner" style="display: none; position: sticky;inset: 0 0 auto 0;background-color: #000;"></div> <div class="module__inner module-t-xl module-b-xl"> <div class="module__container"> <div class="flex bannex-text-image"> <div class="module__text">  <h1 > Let’s do something<br>life-changing together </h1> <h2></h2> <div class="module__content"> <p style="font-weight: 400;">Making viral vectors is in our DNA. Backed by decades of experience and deep technical expertise, our CDMO services are trusted by some of the world’s top cell and gene therapy companies.</p> <p>We can help you transform the lives of patients.</p> </div> <a class="button button--solid button--plum-purple" href="https://oxb.com/contact/" > <div class="button__bg"></div> <span class="button__text">Let's Talk</span> </a>  </div> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/09/oxb-home-banner-new.png" width="1601" height="1667" alt="" /> </div> </div> </div> </div> <div class="module__bgimg" style="opacity: 1;background: url('https://oxb.com/wp-content/uploads/2024/09/oxb-home-banner-bg.png') no-repeat center center;"></div> </div> </section> <section id="notification" class="module module-notification text-light bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-grad-one"> <div class="module__inner module-t-vs module-b-vs"> <div class="module__container"> <div class="flex notification-text-image"> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/11/Event-Image-Hexagon.webp" width="170" height="161" alt="Event Image Hexagon" /> </div> <div class="module__text">  <div class="module__content"> <h2>Upcoming webinar</h2> <p>Accelerating Viral Vector Manufacturing:<br /> The Use of Automation from Early Stage to QC Release</p> <p>Monday, 9th December 2024</p> </div> <a class="button button--solid button--white" href="https://oxb.com/event/webinar-accelerating-viral-vector-manufacturing-the-use-of-automation-from-early-stage-to-qc-release-xtalks/" > <div class="button__bg"></div> <span class="button__text">Register now</span> </a>  </div> </div> </div> </div> </div> </section> <section class="module module-focus text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-xl module-b-none"> <div class="module__container"> <h2 class="lg-text-center">OXB by the numbers</h2>  <div class="module__facts grid grid-layout-cols-2 sm-grid-layout-cols-2 md-grid-layout-cols-4 lg-grid-layout-cols-4 xl-grid-layout-cols-4 p-y-md"> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="25" data-speed="2000">0</span>+</h2> <p class="m-none">Years of viral vector experience </p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="1st" data-speed="10">0</span><sup>st</sup></h2> <p class="m-none">Commercial supplier of lentiviral vectors for a CAR-T therapy</p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="550" data-speed="2000">0</span>+</h2> <p class="m-none">GMP batches released</p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="15" data-speed="2000">0</span></h2> <p class="m-none">GMP suites in three countries</p> </div> </div>  </div> </div> </div> </section> <section class="module module-focus text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-none module-b-md"> <div class="module__container">  <div class="module__facts grid grid-layout-cols-2 sm-grid-layout-cols-2 md-grid-layout-cols-4 lg-grid-layout-cols-4 xl-grid-layout-cols-4 p-y-md"> <div class="module__fact"> <h2 class="m-none text-blue">~<span class="timer" data-to="50" data-speed="2000">0</span></h2> <p class="m-none">Client programmes</p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="90" data-speed="2000">0</span>%</h2> <p class="m-none">Qualified assays and methods performed in-house</p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="50" data-speed="2000">0</span>+</h2> <p class="m-none">Successful audits</p> </div> <div class="module__fact"> <h2 class="m-none text-blue"><span class="timer" data-to="1" data-speed="5">0</span><sup>st</sup></h2> <p class="m-none">Company to treat patients in-vivo with lentiviral vector gene therapy</p> </div> </div>  </div> </div> </div> </section> <section class="module module-content text-light bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-none"> <div class="module__container">  <div class="module__content"> <div class="flex image-left"> <div class="module__text align-left"> <p>We offer end-to-end development and production capabilities for many viral vector types, from plasmid design and optimisation to clinical and commercial GMP manufacturing. These capabilities are supported by robust control systems, advanced analytical methods, and in-depth knowledge of global regulatory requirements.</p> </div> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/09/oxb-about.png" width="925" height="925" alt="scientist in lab" /> </div> </div> </div>  </div> </div> <div class="module__bgimg" style="opacity: 1;"></div> </div> </section> <section class="module module-content text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-none"> <div class="module__container">  <div class="module__content"> <div class="flex image-right"> <div class="module__text align-left"> <h2>About OXB</h2> <p>We are deeply committed to producing high-quality viral vectors, recognizing their crucial role in cell and gene therapies that bring hope to patients around the world. At OXB, we embrace this responsibility and understand that your success is our success.</p> </div> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/09/about-oxb.png" width="572" height="506" alt="scientist in lab" /> </div> </div> </div>  </div> </div> </div> </section> <section class="module module-content text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-none"> <div class="module__container">  <div class="module__content"> <div class="flex image-left"> <div class="module__text align-left"> <p>Whether you are an early-stage company racing to demonstrate proof-of-concept or have an established pipeline with assets advancing towards commercialization, we have the agility to meet your dynamic and evolving needs for high quality vectors.</p> <a class="button button--solid button--plum-purple" href="https://oxb.com/about/" > <div class="button__bg"></div> <span class="button__text">Read more about us</span> </a> </div> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/09/Rectangle-1315-1.png" width="572" height="507" alt="scientist in lab" /> </div> </div> </div>  </div> </div> </div> </section> <section class="module module-content text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-sm"> <div class="module__container">  <div class="module__content"> <div class="flex image-right"> <div class="module__text align-left"> <h2>Our cell and gene therapy services</h2> <p>We have extensive end-to-end capabilities in lentivirus and AAV vectors, as well as adenovirus systems and can help you design, develop, manufacture and deliver the life-changing medicines of tomorrow.</p> <a class="button button--solid button--plum-purple" href="https://oxb.com/services/" > <div class="button__bg"></div> <span class="button__text">Discover our services</span> </a> </div> <div class="module__image"> <img src="https://oxb.com/wp-content/uploads/2024/09/oxb-servces.png" width="572" height="506" alt="scientists in lab" /> </div> </div> </div>  </div> </div> </div> </section>  <section class="module module-content-tab text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-sm"> <div class="module__container">  <div class="module__content"> <h2 class="lg-text-center">Our platforms</h2> <div class="tabs"> <div class="tabs__nav flex flex--col lg-flex--row flex--justify-flex-start button-style-solid"> <div class="button button--tab" aria-controls="tab-lentivector-platform" aria-selected="true" role="tab" data-action="tabs" data-tab-target="tab-lentivector-platform" id="tab-nav-lentivector-platform" > LentiVector<sup style="line-height: 0em">®</sup> platform </div> <div class="button button--tab" aria-controls="tab-inaavate™-platform" aria-selected="true" role="tab" data-action="tabs" data-tab-target="tab-inaavate™-platform" id="tab-nav-inaavate™-platform" tabindex='-1' > inAAVate™ platform </div> <div class="button button--tab" aria-controls="tab-tech-transferred-in" aria-selected="true" role="tab" data-action="tabs" data-tab-target="tab-tech-transferred-in" id="tab-nav-tech-transferred-in" tabindex='-1' > Tech transferred-in </div> </div> <div class="tabs__panel flex flex--wrap flex--row flex--justify-space-between image-right" aria-labelledby="tab-nav-lentivector-platform" id="tab-lentivector-platform" role="tabpanel" data-tab="tab-lentivector-platform" > <div class="tabs__image"> <img class="object-fit-cover" src="https://oxb.com/wp-content/uploads/2024/09/Our-Platform-Lenti-1-e1726752859466.png" alt="scientist in lab" /> </div> <div class="tabs__text with-image"> <h3 class="tab-title"><span>LentiVector<sup style="line-height: 0em">®</sup> platform</span></h3> <p>Achieve reliable and impressive results with our innovative LentiVector<sup>®</sup> platform, the first commercially approved lentiviral gene delivery technology.</p> <a class="button button--solid button--plum-purple" href="https://oxb.com/lentivector/" > <div class="button__bg"></div> <span class="button__text">LentiVector<em><sup>®</sup></em> platform</span> </a> </div> </div> <div class="tabs__panel flex flex--wrap flex--row flex--justify-space-between image-right" aria-labelledby="tab-nav-inaavate™-platform" id="tab-inaavate™-platform" role="tabpanel" data-tab="tab-inaavate™-platform" > <div class="tabs__image"> <img class="object-fit-cover" src="https://oxb.com/wp-content/uploads/2024/09/Platform-Inaave-e1726752840843.png" alt="scientist in lab" /> </div> <div class="tabs__text with-image"> <h3 class="tab-title"><span>inAAVate™ platform</span></h3> <p>Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.</p> <a class="button button--solid button--plum-purple" href="https://oxb.com/adeno-associated-virus-aav/" > <div class="button__bg"></div> <span class="button__text">inAAVate™ platform</span> </a> </div> </div> <div class="tabs__panel flex flex--wrap flex--row flex--justify-space-between image-right" aria-labelledby="tab-nav-tech-transferred-in" id="tab-tech-transferred-in" role="tabpanel" data-tab="tab-tech-transferred-in" > <div class="tabs__image"> <img class="object-fit-cover" src="https://oxb.com/wp-content/uploads/2024/09/Our-Platform-Tech-Transferred-in-e1726752818839.png" alt="scientist in lab" /> </div> <div class="tabs__text with-image"> <h3 class="tab-title"><span>Tech transferred-in</span></h3> <p>Alongside our own LentiVector<sup>®</sup> and inAAVate™ platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.</p> </div> </div> </div> </div>  </div> </div> </div> </section> <section class="module module-post-grid text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-sm module-b-sm"> <div class="module__container">  <h2 class="m-b-sm lg-text-center">Discover our latest news</h2> <div class="post-grid m-y-sm md-m-y-md lg-m-y-lg swiper news-slider"> <div class="grid grid-gap-md lg-grid-gap-lg xl-grid-gap-xl grid-layout-cols-1 md-grid-layout-cols-2 lg-grid-layout-cols-4 swiper-wrapper"> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Nov 20, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/oxb-to-host-a-free-webinar-on-accelerating-development-of-viral-vectors-through-automated-manufacturing-and-analytical-development/">OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled “Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release” will be held on Monday 9 December 2024 at 16:00 GMT / 11:00 EST / 17:00 CET. The webinar will feature presentations by: André Raposo, PhD, Director, Innovation Department at OXB Gareth McCathie, PhD, Group Lead, Innovation Department at OXB Thomas Evans, Principal Scientist, Innovation Department at OXB The speakers will showcase OXB’s automation expertise in viral vector manufacturing, highlighting how automated systems and digital tools are used to optimise production processes and analytical workflows. The presentation will include case studies on transfection optimisation and the implementation of automated analytical methods such as qPCR, ELISA, and cell-based assays. The presentations will be followed by a live Q&A session. To register for the webinar, please click here. Enquiries OXB: Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 509 737 / E: partnering@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/oxb-to-host-a-free-webinar-on-accelerating-development-of-viral-vectors-through-automated-manufacturing-and-analytical-development/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Nov 18, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/board-changes-november-2024/">Board changes</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 18 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Colin Bond as a Non-Executive Director effective 1 January 2025. Mr. Bond will also join the Audit Committee as part of succession planning ahead of Stuart Henderson losing his independent status as a Non-Executive Director in June 2025. Colin Bond has a wealth of international experience in the CDMO and biopharma industries and was most recently Chief Financial Officer of Sandoz listed on the SIX Swiss Exchange, where he played a key role in the company’s successful spin-off from Novartis. Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma and Evotec. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange, for ten years until May 2023. He is currently Chair of the Audit Committee of BioPharma Credit PLC on the London Stock Exchange and a member of the Supervisory Board of Formycon AG. During his early career, Mr. Bond worked as a pharmacist, auditor and management consultant for Procter & Gamble, Arthur Andersen and PwC. Mr. Bond is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. He holds a BSc in Pharmacy from Aston University and an MBA from London Business School. Additionally, OXB announces that Leone Patterson has informed the Board of her decision to step down as a Non-Executive Director on 31 December 2024 in order to focus on her new responsibilities following her recent appointment as Chief Business and Financial Officer of Zymeworks. Dr. Roch Doliveux, Chair of OXB, commented: “Colin is a highly strategic operator with extensive international CDMO and healthcare sector expertise plus first-rate technical accounting credentials. He is well regarded by the investment community and has overseen organisations that have undergone significant growth and transformation. On behalf of the Board, I am delighted to welcome Colin to OXB and thoroughly look forward to working with him. I would also like to thank Leone for her sharp analytical insights and active contributions to OXB during her tenure on the Board and wish her the very best with her new responsibilities.” Colin Bond, incoming Board member at OXB, said: “OXB’s position as a leader in cell and gene therapy manufacturing, combined with its innovative approach and strong client partnerships, presents a compelling opportunity that I have recently watched with interest. I am excited to join the Board at this important time and look forward to working with the team to support OXB’s continued growth and success in enabling the delivery of life-changing therapies to patients worldwide.” Relevant disclosures Save as disclosed, there are no disclosures required to be made in accordance with UKLR 6.4.8(R). Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/board-changes-november-2024/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Nov 15, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/oxb-to-present-at-the-jefferies-london-healthcare-conference/">OXB to present at the Jefferies London Healthcare Conference</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 15 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Frank Mathias, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Tuesday, 19 November 2024 at 10:00am GMT. Dr. Lucy Crabtree, Chief Financial Officer, will also be participating in the conference. The presentation will be made available in the Investors section of OXB’s website at www.oxb.com. Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/oxb-to-present-at-the-jefferies-london-healthcare-conference/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Sep 23, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/oxford-biomedica-plc-interim-results-for-the-six-months-ended-30-june-2024/">Oxford Biomedica PLC interim results for the six months ended 30 June 2024</a></h4> <p class="card__description m-b-sm"> Delivering Pure-Play CDMO Growth Strategy Continued execution of “One OXB” strategy with global integration progressing across UK, US and French operations Existing near-term and medium-term financial guidance reiterated, supported by positive growth trajectory of the business Continued strong demand for OXB’s CDMO services, with an increase in number of late stage programmes Client portfolio is maturing and now includes 37 clients and 48 programmes as of September 2024 (September 2023:24 clients and 41 programmes), representing a growth of 54% for clients and 17% for programmes year-on-year Successfully onboarded multiple new clients, including signing 7 early-stage AAV programmes in the US Currently supporting late stage activities for 4 clients preparing for commercial launch of CAR-T products, compared to 1 late stage programme in September 2023 Strong commercial KPIs underpin expected momentum in second half of 2024 and beyond: Contracted value of client orders in the first eight months of the year reflect strong demand for CDMO services at approximately £94 million; this is supported by a high level of GMP suite utilisation for 2025 The total potential revenue pipeline grew by 29% from $438 million to $565 million, since the start of the year (as of 13 September 2024) Post-period end, Lucinda Crabtree joined as CFO on 2 September; transition process well-progressed Oxford, UK – 23 September 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces interim results for the six months ended 30 June 2024. Dr. Frank Mathias, OXB’s Chief Executive Officer, said: “The first half of 2024 has been a period of significant progress for OXB as we continue to execute our multi-vector, multi-site ‘One OXB’ strategy. “The integration of our global network of sites is progressing well, delivering operational benefits that enhance our ability to meetdiverse client needs and accelerate project timelines. We’ve experienced strong demand across our viral vector services, with particularly robust revenue growth in lentiviral vector manufacturing. Importantly, we’re also seeing encouraging progress in AAV,including the signing of several new early stage programmes in the US. “Our commercial momentum is strong across all our key regions – the UK, US and France. We’re particularly pleased with the growth in our late-stage programmes, now supporting late stage activities for four clients preparing for commercial launch of CAR-T products. “The positive trajectory of our key performance indicators, including our growing revenue backlog and the high level of GMP suite reservations for 2025, gives us confidence in our future performance. These metrics reflect the increasing maturity ofour client programmes and the growing demand for our services in the cell and gene therapy sector. “As we look ahead, we remain focused on further integrating our operations and growing our global portfolio of clients and projects across all stages of clinical development. I’m proud of the OXB team whose expertise and dedication are driving our achievements, enabling our clients to deliver life-changing therapies to patients and create long-term value for our shareholders.” FINANCIAL HIGHLIGHTS (including post-period events) Double-digit revenue growth; total revenues increased by 18% to £50.8 million (H1 2023: £43.1 million). Organic revenue growth was 38%. Organic growth excludes the impact of the acquisition of OXB France and the loss of revenues from Homology Medicines, Inc (“Homology”). Revenue growth was driven by higher levels of manufacturing and commercial development activity, including: New client acquisition and revenue growth in lentiviral vector manufacturing as a result of an increase in the number ofbatches manufactured and clients transitioning to Process C, OXB’s best-in-class perfusion bioreactor process for lentiviral vector manufacturing. New contributions from OXB France following the acquisition of ABL Europe in January 2024, total revenues in France of £5.7 million in H1 2024. Offset by a decline in US revenues due to Homology ceasing clinical activities, revenues from Homology in H1 2024 were £0.2 million (H1 2023: £12.9 million). Lower cost base as a result of the 2023 reorganisation: Operating EBITDA loss of £(20.3) million (H1 2023: £(33.7 million) and operating loss of £(32.2) million (H1 2023: £(50.7) million). Sufficient capital to achieve current strategic plan: Cash at 30 June 2024 was £81.4 million (31 Dec 2023: £103.7 million); Net cash was £41.7 million (31 Dec 2023: £65.2 million). Commercial KPIs underpin expected momentum for the second half of 2024 and beyond: The contracted value of client orders1 signed during the first 8 months of 2024 was approximately £94 million as at 31 August 2024. Revenue backlog<sup>2</sup>as at 31 August 2024 stood at approximately £120 million, compared to £94 million at 31 December 2023. This is the amount of future revenue available to earn from current orders.   OUTLOOK AND FINANCIAL GUIDANCE The Group reiterates its existing near-term and medium-term financial guidance communicated to the market: 2024 total Group revenues of between £126 million and £134 million, with a three-year revenue CAGR of more than 35% for 2023-2026. Low double-digit Operating EBITDA loss in 2024, including the impact of the acquisition of OXB France and investment in talent to support increased late stage client activity in 2025. The Group expects to achieve Operating EBITDA margins in excess of 20% by the end of 2026, and to be profitable on an EBITDA level in 2025. 1 Contracted value of client orders represent the value of customer orders for which the customer has signed a financial commitment, whereby any changes to agreed values will be subject to either change orders or cancellation fees. 2 Revenue backlog represents ordered CDMO revenues available to earn. It is calculated on a cumulative basis by adding new contracted client orders less the value of revenues already recognised or no longer available after project scope adjustments or cancellations. ANALYST BRIEFING OXB’s management team, led by Dr. Frank Mathias, CEO, Dr. Lucinda Crabtree, CFO and Dr. Sebastien Ribault, CBO will behosting a briefing and Q&A session for analysts at 13:00 BST / 8:00 EST today, 23 September, at Chartered Accountants Hall, One Moorgate Place, London EC2R 6EA, United Kingdom. A live webcast of the presentation will be available via this link. The presentation will be available on OXB’s website at www.oxb.com If you would like to dial in to the call and ask a question during the live Q&A, please email OXB@icrhealthcare.com Read the OXFORD BIOMEDICA PLC interim results for the six months ended 30th June 2024: Download PDF here NOTES Unless otherwise defined, terms used in this announcement shall have the same meaning as those used in the Annual report and accounts.   ENQUIRIES Oxford Biomedica plc T: +44 (0)1865 509 737/ E: ir@oxb.com Sophia Bolhassan, Head of Investor Relations ICR Consilium T: +44 (0)20 3709 5700 / E: OXB@icrhealthcare.com Mary-Jane Elliott Angela Gray Davide Salvi RBC Capital Markets (Joint Corporate Brokers): T: +44 (0)20 7653 4000 Rupert Walford Kathryn Deegan JP Morgan (Joint Corporate Brokers): T: +44 (0)207 1347329 James Mitford Manita Shinh Jem de los Santos ABOUT OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early stage development tocommercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/oxford-biomedica-plc-interim-results-for-the-six-months-ended-30-june-2024/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Sep 18, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/oxford-biomedica-rebrands-as-oxb-reinforcing-transformation-into-leading-global-cell-and-gene-therapy-cdmo/">Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO</a></h4> <p class="card__description m-b-sm"> Oxford Biomedica is rebranding as OXB, unveiling a more modern and recognisable visual identity that reinforces its transformation into a global pure-play cell and gene therapy CDMO. https://oxb.com/wp-content/uploads/2024/09/OXB-Logo-Animation-New-Colour-With-Branding-Context.mp4   The new identity reflects OXB’s unique combination of technical excellence, innovation and unwavering commitment to deliver consistent high quality at every stage of viral vector development and manufacturing. The new branding represents the agile execution and creativity that enable OXB to deliver on clients’ goals, while also conveying accountability, professionalism and teamwork – core values that underpin OXB’s mission. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “The launch of our new brand identity reinforces OXB’s significant transformation into a leading pure-play cell and gene therapy CDMO. This rebranding is more than just a new look – it reflects the global nature of our operations and our deep commitment to the success of our clients’ drug development programmes. As OXB, with our new capabilities and global footprint, we are ideally positioned to communicate our end-to-end services to current and potential clients, and to interact with them from early-stage development through to commercial manufacturing.”     Enquiries OXB: Sebastien Ribault, Chief Commercial Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube </p> <a href="https://oxb.com/oxford-biomedica-rebrands-as-oxb-reinforcing-transformation-into-leading-global-cell-and-gene-therapy-cdmo/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Sep 2, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/lucinda-crabtree-joins-oxford-biomedica-as-chief-financial-officer-today/">Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined Oxford Biomedica as Chief Financial Officer (CFO) and board member. Lucinda’s appointment was previously announced on 17 July 2024. Lucinda Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team across the US and Germany until the company’s acquisition by Novartis. Previously, she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company. Lucinda also brings extensive experience from the investment and banking sectors, having held roles at institutions including Woodford Investment Management, Goldman Sachs, and Jefferies. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “We are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board member today. Lucy brings a wealth of experience from her roles as a CFO and time as a healthcare investor and equity research analyst. Her experience will be invaluable as we grow our international position as a leading cell and gene therapy CDMO.” Lucinda Crabtree, Chief Financial Officer of Oxford Biomedica said: “I am excited to be joining Oxford Biomedica as CFO today. I firmly believe in the Company’s growth strategy and am looking forward to working with the Board and the rest of the leadership team. Together, I’m confident we will fulfil our mission of enabling our growing client base to deliver life-changing therapies to patients.” -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: Oxford Biomedica) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetravectaTM system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/lucinda-crabtree-joins-oxford-biomedica-as-chief-financial-officer-today/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Aug 27, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/oxford-biomedica-to-host-a-free-webinar-showcasing-its-aav-expertise/">Oxford Biomedica to host a free webinar showcasing its AAV expertise</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar on its adeno-associated virus (AAV) development expertise and showcase their recent breakthroughs. The webinar titled “Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity” will feature presentations by: Sarah Laughlin-Toth, PhD, Senior Scientist, Analytical Development at Oxford Biomedica Thomas Thiers, Downstream Scientist, Purification Sciences at Oxford Biomedica Alex Meola, Associate Director, AAV Downstream Process Development at Oxford Biomedica The speakers will discuss how advanced characterisation of AAV capsids, including their contents and surface properties, provides crucial insights into factors affecting product quality and potency. They will explore the impacts of capsid modifications such as VP1 deamidation, production conditions including bioreactor time and AAV localisation, and capsid heterogeneity on AAV products. This knowledge is vital for enhancing the development and manufacturing of AAV-based therapies, with potential implications for improving product efficacy and patient safety. The webinar will be held at 16:00 BST / 11:00 EDT / 17:00 CET on Wednesday 11 September 2024, followed by a live Q&A session. To register for the webinar, please click here. Enquiries: Oxford Biomedica plc: Sebastien Ribault, Chief Commercial Officer – T: +44 (0) 1865 509 737 / E: partnering@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: Oxford Biomedica) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta<sup>TM</sup> system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/oxford-biomedica-to-host-a-free-webinar-showcasing-its-aav-expertise/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> <div class="card swiper-slide"> <div class="card__inner"> <div class="card-meta flex"> <p class="news-cat">Oxford, UK</p> <p class="news-date">Aug 8, 2024</p> </div> <h4 class="card__title m-b-sm"><a class="text-blue hover-text-pink" href="https://oxb.com/half-year-trading-update-and-notice-of-interim-results/">Half year trading update and notice of interim results</a></h4> <p class="card__description m-b-sm"> Oxford, UK – 8 August 2024: Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by Oxford Biomedica’s growing market share in the expanding cell and gene therapy market Contracted value of client orders in the first seven months of the year reflective of strong demand for CDMO services at approximately £80 million Revenue backlog stood at approximately £113 million at 31 July 2024; high level of GMP suite reservation for 2025 gives increased visibility and underpins confidence in forecasts With increasing demand for services, Oxford Biomedica to invest in talent to support future growth, therefore low double-digit Operating EBITDA loss expected in 2024; 2025 EBITDA profitability outlook maintained due to continued cost discipline and a measured approach to operational spend Oxford, UK – 8 August 2024: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides a trading update for the first half of 2024. Additionally, the Company announces that it will report its Interim Results for the six months ended 30 June 2024 on Monday 23 September 2024. Strong trading for H1 2024 and reconfirmed financial guidance Oxford Biomedica has continued to see strong momentum in 2024 with revenues for the first half expected to be approximately £50 million. As previously communicated, revenues are expected to be second-half weighted, with contracted client orders providing a high degree of visibility. The Company reiterates revenue guidance for the full year within the £126 million to £134 million range. The first half of 2024 is expected to result in a negative Operating EBITDA with a positive Operating EBITDA expected in the second half, due to the effectiveness of the Company’s strategic initiatives, including streamlining of operations and expected strong revenue growth in the second half. With an increase in late-stage client activity expected in 2025, Oxford Biomedica will invest in building its technical and operational workforce to support this demand. With this investment in talent to support revenue growth, the Company expects a low double-digit Operating EBITDA loss for the full year 2024. As communicated at the full year results, 2024 Operating EBITDA includes a mid to high single digit loss from the recently acquired ABL Europe business (renamed “Oxford Biomedica (France)”), which was fully funded by cash received from Institut Mérieux prior to completion of the acquisition. Oxford Biomedica reiterates its medium-term financial guidance of a three-year revenue CAGR in excess of 35% for 2023-2026, to be profitable on an Operating EBITDA level in 2025, with Operating EBITDA margins in excess of 20% by the end of 2026. Oxford Biomedica’s cash position remains strong with £81 million cash as of 30 June 2024. This includes the proceeds from a EUR 20 million (£16.9 million) investment by TSGH SAS, a subsidiary of Institut Mérieux SA, following the acquisition of Oxford Biomedica (France). Strong demand for CDMO services Demand for Oxford Biomedica’s CDMO services has remained strong across all key viral vector types. The contracted value of client orders signed during 2024 was approximately £80 million as at 31 July 2024, in line with the Company’s expectations. Based on current business development activities and Oxford Biomedica’s growing market share, the cadence of signing orders is expected to increase in the second half of the year. Revenue backlog[1] (including France) stood at approximately £113 million at 31 July 2024, compared to £104 million at 31 March 2024. GMP suite reservation for 2025 has been high, further bolstering confidence in future revenue delivery. Clients transitioning from early stage manufacturing to late stage and commercial activities have moved from a batch reservation model to a binding forecast model, providing increased revenue visibility. Oxford Biomedica has made significant progress with its new commercial, multi-site, multi-vector strategy. The Company has successfully transferred its lentiviral vector capabilities to its Bedford, Massachusetts site and commenced its first lentiviral vector programme in the US. Plans are underway to enable the Company’s French sites to provide similar lentiviral vector services by the end of 2024. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “Oxford Biomedica has seen continued strong momentum in 2024, reinforcing our position as a world-leading cell and gene therapy CDMO. Our multi-site, multi-vector strategy is gaining traction, demonstrated by our strong revenue backlog and growing order book. These strong KPIs and high GMP suite reservation for 2025 provide us with confidence in our growth trajectory and our ability to capitalise on the growing opportunities in the cell and gene therapy market.” Notice of Interim Results Oxford Biomedica expects to report its Interim Results for the six months ended 30 June 2024 on Monday 23 September 2024. A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA. [1] Revenue backlog represents ordered CDMO revenues available to earn. The value of customer orders included in revenue backlog only includes the value of work for which the customer has signed a financial commitment for Oxford Biomedica to undertake, whereby any changes to agreed values will be subject to either change orders or cancellation fees. Enquiries: Oxford Biomedica plc: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: Oxford Biomedica) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta<sup>TM</sup> system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. </p> <a href="https://oxb.com/half-year-trading-update-and-notice-of-interim-results/"><img src="/wp-content/uploads/2024/09/icn-read-more.svg" width="56" height="56" alt="read more"></a> </div> </div> </div> </div> <div class="button-row text-center"> <a class="button button--solid button--plum-purple" href="https://oxb.com/news/"> <div class="button__bg"></div> <span class="button__text">More news</span> </a> </div>  </div> </div> <div class="module__bgimg" style="background: url('https://oxb.com/wp-content/uploads/2024/09/oxb-home-banner-bg.png') no-repeat center center;"></div> </div> </section> <section id="subscribe" class="module module-showcase module-showcase-type-newsletter text-dark bg-pink angle-none angle-top-left angle-bottom-left "> <div class="module__wrapper bg-white"> <div class="module__inner module-t-md module-b-md"> <div class="module__container">  <div class="module__content"> <div class="flex"> <div class="module__text align-left"> <h2 class="lg-text-center m-b-sm">Stay in touch</h2> <h3 class="lg-text-center m-b-xl">Subscribe to receive OXB's latest news, events and insights</h3> </div> <div class="module__form"> <div class="module__showcase_content grid grid-gap-md"> <div class="module__row grid grid-gap-md grid-layout-cols-1 md-grid-layout-cols-1 lg-grid-layout-cols-1 grid-align-center"> <div class="module__column">  <div class="column-text"> <script type="text/javascript"></script> <div class='gf_browser_chrome gform_wrapper gravity-theme gform-theme--no-framework' data-form-theme='gravity-theme' data-form-index='0' id='gform_wrapper_5' ><div id='gf_5' class='gform_anchor' tabindex='-1'></div> <div class='gform_heading'> <h2 class="gform_title">Stay in touch - Subscribe</h2> <p class='gform_description'></p> </div><form method='post' enctype='multipart/form-data' target='gform_ajax_frame_5' id='gform_5' action='/#gf_5' data-formid='5' novalidate> <div class='gform-body gform_body'><div id='gform_fields_5' class='gform_fields top_label form_sublabel_below description_below validation_below'><div id="field_5_3" class="gfield gfield--type-text gfield--width-half gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible" data-js-reload="field_5_3" ><label class='gfield_label gform-field-label' for='input_5_3'>First name<span class="gfield_required"><span class="gfield_required gfield_required_text">(Required)</span></span></label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_5_3' type='text' value='' class='large' placeholder='Enter first name...' aria-required="true" aria-invalid="false" /> </div></div><div id="field_5_4" class="gfield gfield--type-text gfield--width-half gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible" data-js-reload="field_5_4" ><label class='gfield_label gform-field-label' for='input_5_4'>Last name<span class="gfield_required"><span class="gfield_required gfield_required_text">(Required)</span></span></label><div class='ginput_container ginput_container_text'><input name='input_4' id='input_5_4' type='text' value='' class='large' placeholder='Enter last name..' aria-required="true" aria-invalid="false" /> </div></div><div id="field_5_1" class="gfield gfield--type-email gfield--width-full gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible" data-js-reload="field_5_1" ><label class='gfield_label gform-field-label' for='input_5_1'>Email<span class="gfield_required"><span class="gfield_required gfield_required_text">(Required)</span></span></label><div class='ginput_container ginput_container_email'> <input name='input_1' id='input_5_1' type='email' value='' class='large' placeholder='example@gmail.com' aria-required="true" aria-invalid="false" /> </div></div><div id="field_5_7" class="gfield gfield--type-captcha gfield--width-full field_sublabel_below gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible" data-js-reload="field_5_7" ><label class='gfield_label gform-field-label' for='input_5_7'>CAPTCHA</label><div id='input_5_7' class='ginput_container ginput_recaptcha' data-sitekey='6Ldol9wiAAAAABW5mX2FxPdM-RktR196Diu19SxM' data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'></div></div><fieldset id="field_5_6" class="gfield gfield--type-checkbox gfield--type-choice gfield--width-full gfield_contains_required field_sublabel_below gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible" data-js-reload="field_5_6" ><legend class='gfield_label gform-field-label gfield_label_before_complex' >Privacy policy<span class="gfield_required"><span class="gfield_required gfield_required_text">(Required)</span></span></legend><div class='ginput_container ginput_container_checkbox'><div class='gfield_checkbox' id='input_5_6'><div class='gchoice gchoice_5_6_1'> <input class='gfield-choice-input' name='input_6.1' type='checkbox' value='Agree' id='choice_5_6_1' /> <label for='choice_5_6_1' id='label_5_6_1' class='gform-field-label gform-field-label--type-inline'>I have read and agree to the <a target="_blank" href="/privacy-policy">privacy policy</a>.</label> </div></div></div></fieldset></div></div> <div class='gform_footer top_label'> <input type='submit' id='gform_submit_button_5' class='gform_button button gform-button--width-full' value='Subscribe' onclick='if(window["gf_submitting_5"]){return false;} if( !jQuery("#gform_5")[0].checkValidity || jQuery("#gform_5")[0].checkValidity()){window["gf_submitting_5"]=true;} ' onkeypress='if( event.keyCode == 13 ){ if(window["gf_submitting_5"]){return false;} if( !jQuery("#gform_5")[0].checkValidity || jQuery("#gform_5")[0].checkValidity()){window["gf_submitting_5"]=true;} jQuery("#gform_5").trigger("submit",[true]); }' /> <input type='hidden' name='gform_ajax' value='form_id=5&title=1&description=1&tabindex=0&theme=gravity-theme' /> <input type='hidden' class='gform_hidden' name='is_submit_5' value='1' /> <input type='hidden' class='gform_hidden' name='gform_submit' value='5' /> <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' /> <input type='hidden' class='gform_hidden' name='state_5' value='WyJ7XCI2LjFcIjpcIjI3ZDZlYWY2Yjg1YjUyYzQ3ZTFiMmFiN2ZmNTMwOTk4XCJ9IiwiODM1MGRmNTA5MzE5NGNjOWQwNDMwNjIzMTMyMTQ3MzciXQ==' /> <input type='hidden' class='gform_hidden' name='gform_target_page_number_5' id='gform_target_page_number_5' value='0' /> <input type='hidden' class='gform_hidden' name='gform_source_page_number_5' id='gform_source_page_number_5' value='1' /> <input type='hidden' name='gform_field_values' value='' /> </div> </form> </div> <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_5' id='gform_ajax_frame_5' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'></iframe> <script type="text/javascript"> /* <![CDATA[ */ gform.initializeOnLoaded( function() {gformInitSpinner( 5, 'https://oxb.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery('#gform_ajax_frame_5').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_5');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_5').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_5').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_5').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_5').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_5').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_5').val();gformInitSpinner( 5, 'https://oxb.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery(document).trigger('gform_page_loaded', [5, current_page]);window['gf_submitting_5'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_5').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_5').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [5]);window['gf_submitting_5'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_5').text());}else{jQuery('#gform_5').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "5", currentPage: "current_page", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_5" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_5"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_5" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; jQuery( document ).trigger( 'gform_post_render', [5, current_page] ); gform.utils.trigger( { event: 'gform/postRender', native: false, data: { formId: 5, currentPage: current_page } } ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );} ); /* ]]> */ </script> </div> </div> </div> </div> </div> </div> </div>  </div> </div> <div class="module__bgimg" style="opacity: 1;background: url('https://oxb.com/wp-content/uploads/2024/09/oxb-subscribe-bg.png') no-repeat center center;"></div> </div> </section> </main> <footer class="site-footer bg-blue-dark p-y-sm md-p-y-md lg-p-y-lg xl-p-y-xl xxl-p-y-xxl"> <div class="container flex flex--wrap flex--justify-space-between xl-flex--align-flex-start flex--align-start"> <div class="site-footer__logo"> <figure> <a href="https://oxb.com" title="Visit Homepage"> <img src="https://oxb.com/wp-content/uploads/2024/09/OXB-Logo.svg" width="122" height="63" alt="OXB"> </a> </figure> </div> <div class="site-footer__nav"> <ul class="p-none m-none list-unstyled"> <li> <a class="text-white hover-text-red no-underline" href="https://oxb.com/privacy-policy/" target=""> Privacy policy </a> </li> <li> <a class="text-white hover-text-red no-underline" href="https://oxb.com/cookies-policy/" target=""> Cookies policy </a> </li> <li> <a class="text-white hover-text-red no-underline" href="https://oxb.com/wp-content/uploads/2024/04/OxfordBiomedica-Modern-Slavery-Act-2024.pdf" target="_blank"> Modern slavery </a> </li> <li> <a class="text-white hover-text-red no-underline" href="https://oxb.com/legal-policy/" target=""> Legal notice </a> </li> <li> <a class="text-white hover-text-red no-underline" href="https://oxb.com/media-assets/" target=""> Media Assets </a> </li> </ul> </div> </div> <div class="container flex flex--col lg-flex--row flex--justify-space-between flex--align-start oxb-secondary-footer"> <div class="site-footer__address"> <p class="text-left text-white">Oxford Biomedica PLC, Windrush Court, Transport Way, Oxford, OX4 6LT, United Kingdom</p> </div> <div class="site-footer__additional_content"> <p class="text-center text-white">© 2024 Oxford Biomedica PLC | Company No. 03252665 | VAT No. GB 663 6533 21</p> </div> <div class="site-footer__social"> <ul> <li> <a href="https://www.youtube.com/user/OxfordBioMedica" title="YouTube Link" rel="noopener noreferrer" target="_blank"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 576 512"> <path d="M549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z"/> </svg> </a> </li> <li> <a href="https://www.linkedin.com/company/oxford-biomedica/" title="LinkedIn Link" rel="noopener noreferrer" target="_blank"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"> <path d="M100.28 448H7.4V148.9h92.88zM53.79 108.1C24.09 108.1 0 83.5 0 53.8a53.79 53.79 0 0 1 107.58 0c0 29.7-24.1 54.3-53.79 54.3zM447.9 448h-92.68V302.4c0-34.7-.7-79.2-48.29-79.2-48.29 0-55.69 37.7-55.69 76.7V448h-92.78V148.9h89.08v40.8h1.3c12.4-23.5 42.69-48.3 87.88-48.3 94 0 111.28 61.9 111.28 142.3V448z"/> </svg> </a> </li> </ul> </div> </div> </footer> </div> <script> var isIE11 = !!navigator.userAgent.match(/Trident.*rv\:11\./); if(isIE11) { document.body.classList.add('is-ie11'); } </script>  <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KBH23HR8" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <link rel='stylesheet' id='gform_basic-css' href='https://oxb.com/wp-content/plugins/gravityforms/assets/css/dist/basic.min.css?ver=2.8.17' type='text/css' media='all' /> <link rel='stylesheet' id='gform_theme_components-css' href='https://oxb.com/wp-content/plugins/gravityforms/assets/css/dist/theme-components.min.css?ver=2.8.17' type='text/css' media='all' /> <link rel='stylesheet' id='gform_theme_ie11-css' href='https://oxb.com/wp-content/plugins/gravityforms/assets/css/dist/theme-ie11.min.css?ver=2.8.17' type='text/css' media='all' /> <link rel='stylesheet' id='gform_theme-css' href='https://oxb.com/wp-content/plugins/gravityforms/assets/css/dist/theme.min.css?ver=2.8.17' type='text/css' media='all' /> <link rel='stylesheet' id='mediaelement-css' href='https://oxb.com/wp-includes/js/mediaelement/mediaelementplayer-legacy.min.css?ver=4.2.17' type='text/css' media='all' /> <link rel='stylesheet' id='wp-mediaelement-css' href='https://oxb.com/wp-includes/js/mediaelement/wp-mediaelement.min.css?ver=6.6.2' type='text/css' media='all' /> <script type="text/javascript" src="https://oxb.com/wp-content/themes/oxfordbiomedica-wp/dist/js/main.min.js?ver=20241126" id="theme-js-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/dist/dom-ready.min.js?ver=f77871ff7694fffea381" id="wp-dom-ready-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/dist/hooks.min.js?ver=2810c76e705dd1a53b18" id="wp-hooks-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script> <script type="text/javascript" id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script type="text/javascript" id="wp-a11y-js-translations"> /* <![CDATA[ */ ( function( domain, translations ) { var localeData = translations.locale_data[ domain ] || translations.locale_data.messages; localeData[""].domain = domain; wp.i18n.setLocaleData( localeData, domain ); } )( "default", {"translation-revision-date":"2024-07-09 16:06:37+0000","generator":"GlotPress\/4.0.1","domain":"messages","locale_data":{"messages":{"":{"domain":"messages","plural-forms":"nplurals=2; plural=n != 1;","lang":"en_GB"},"Notifications":["Notifications"]}},"comment":{"reference":"wp-includes\/js\/dist\/a11y.js"}} ); /* ]]> */ </script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/dist/a11y.min.js?ver=d90eebea464f6c09bfd5" id="wp-a11y-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/js/jquery.json.min.js?ver=2.8.17" id="gform_json-js"></script> <script type="text/javascript" id="gform_gravityforms-js-extra"> /* <![CDATA[ */ var gform_i18n = {"datepicker":{"days":{"monday":"Mo","tuesday":"Tu","wednesday":"We","thursday":"Th","friday":"Fr","saturday":"Sa","sunday":"Su"},"months":{"january":"January","february":"February","march":"March","april":"April","may":"May","june":"June","july":"July","august":"August","september":"September","october":"October","november":"November","december":"December"},"firstDay":1,"iconText":"Select date"}}; var gf_legacy_multi = []; var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled"},"vars":{"images_url":"https:\/\/oxb.com\/wp-content\/plugins\/gravityforms\/images"}}; var gf_global = {"gf_currency_config":{"name":"Pound Sterling","symbol_left":"£","symbol_right":"","symbol_padding":" ","thousand_separator":",","decimal_separator":".","decimals":2,"code":"GBP"},"base_url":"https:\/\/oxb.com\/wp-content\/plugins\/gravityforms","number_formats":[],"spinnerUrl":"https:\/\/oxb.com\/wp-content\/plugins\/gravityforms\/images\/spinner.svg","version_hash":"0b8d95d62c0d860e729f6806c1b0d7ef","strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved. The content contains the link to return and complete the form."}}; /* ]]> */ </script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/js/gravityforms.min.js?ver=2.8.17" id="gform_gravityforms-js"></script> <script type="text/javascript" defer='defer' src="https://www.google.com/recaptcha/api.js?hl=en&ver=6.6.2#038;render=explicit" id="gform_recaptcha-js"></script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/js/placeholders.jquery.min.js?ver=2.8.17" id="gform_placeholder-js"></script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/assets/js/dist/utils.min.js?ver=50c7bea9c2320e16728e44ae9fde5f26" id="gform_gravityforms_utils-js"></script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/assets/js/dist/vendor-theme.min.js?ver=54e7080aa7a02c83aa61fae430b9d869" id="gform_gravityforms_theme_vendors-js"></script> <script type="text/javascript" id="gform_gravityforms_theme-js-extra"> /* <![CDATA[ */ var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"0b8d95d62c0d860e729f6806c1b0d7ef"}}},"hmr_dev":"","public_path":"https:\/\/oxb.com\/wp-content\/plugins\/gravityforms\/assets\/js\/dist\/"}; /* ]]> */ </script> <script type="text/javascript" defer='defer' src="https://oxb.com/wp-content/plugins/gravityforms/assets/js/dist/scripts-theme.min.js?ver=bab19fd84843dabc070e73326d787910" id="gform_gravityforms_theme-js"></script> <script type="text/javascript" id="mediaelement-core-js-before"> /* <![CDATA[ */ var mejsL10n = {"language":"en","strings":{"mejs.download-file":"Download File","mejs.install-flash":"You are using a browser that does not have Flash player enabled or installed. Please turn on your Flash player plugin or download the latest version from https:\/\/get.adobe.com\/flashplayer\/","mejs.fullscreen":"Fullscreen","mejs.play":"Play","mejs.pause":"Pause","mejs.time-slider":"Time Slider","mejs.time-help-text":"Use Left\/Right Arrow keys to advance one second, Up\/Down arrows to advance ten seconds.","mejs.live-broadcast":"Live Broadcast","mejs.volume-help-text":"Use Up\/Down Arrow keys to increase or decrease volume.","mejs.unmute":"Unmute","mejs.mute":"Mute","mejs.volume-slider":"Volume Slider","mejs.video-player":"Video Player","mejs.audio-player":"Audio Player","mejs.captions-subtitles":"Captions\/Subtitles","mejs.captions-chapters":"Chapters","mejs.none":"None","mejs.afrikaans":"Afrikaans","mejs.albanian":"Albanian","mejs.arabic":"Arabic","mejs.belarusian":"Belarusian","mejs.bulgarian":"Bulgarian","mejs.catalan":"Catalan","mejs.chinese":"Chinese","mejs.chinese-simplified":"Chinese (Simplified)","mejs.chinese-traditional":"Chinese (Traditional)","mejs.croatian":"Croatian","mejs.czech":"Czech","mejs.danish":"Danish","mejs.dutch":"Dutch","mejs.english":"English","mejs.estonian":"Estonian","mejs.filipino":"Filipino","mejs.finnish":"Finnish","mejs.french":"French","mejs.galician":"Galician","mejs.german":"German","mejs.greek":"Greek","mejs.haitian-creole":"Haitian Creole","mejs.hebrew":"Hebrew","mejs.hindi":"Hindi","mejs.hungarian":"Hungarian","mejs.icelandic":"Icelandic","mejs.indonesian":"Indonesian","mejs.irish":"Irish","mejs.italian":"Italian","mejs.japanese":"Japanese","mejs.korean":"Korean","mejs.latvian":"Latvian","mejs.lithuanian":"Lithuanian","mejs.macedonian":"Macedonian","mejs.malay":"Malay","mejs.maltese":"Maltese","mejs.norwegian":"Norwegian","mejs.persian":"Persian","mejs.polish":"Polish","mejs.portuguese":"Portuguese","mejs.romanian":"Romanian","mejs.russian":"Russian","mejs.serbian":"Serbian","mejs.slovak":"Slovak","mejs.slovenian":"Slovenian","mejs.spanish":"Spanish","mejs.swahili":"Swahili","mejs.swedish":"Swedish","mejs.tagalog":"Tagalog","mejs.thai":"Thai","mejs.turkish":"Turkish","mejs.ukrainian":"Ukrainian","mejs.vietnamese":"Vietnamese","mejs.welsh":"Welsh","mejs.yiddish":"Yiddish"}}; /* ]]> */ </script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/mediaelement/mediaelement-and-player.min.js?ver=4.2.17" id="mediaelement-core-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/mediaelement/mediaelement-migrate.min.js?ver=6.6.2" id="mediaelement-migrate-js"></script> <script type="text/javascript" id="mediaelement-js-extra"> /* <![CDATA[ */ var _wpmejsSettings = {"pluginPath":"\/wp-includes\/js\/mediaelement\/","classPrefix":"mejs-","stretching":"responsive","audioShortcodeLibrary":"mediaelement","videoShortcodeLibrary":"mediaelement"}; /* ]]> */ </script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/mediaelement/wp-mediaelement.min.js?ver=6.6.2" id="wp-mediaelement-js"></script> <script type="text/javascript" src="https://oxb.com/wp-includes/js/mediaelement/renderers/vimeo.min.js?ver=4.2.17" id="mediaelement-vimeo-js"></script> <script type="text/javascript"> /* <![CDATA[ */ gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 5) {if(typeof Placeholders != 'undefined'){ Placeholders.enable(); }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); /* ]]> */ </script> <script type="text/javascript"> /* <![CDATA[ */ gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "5", currentPage: "1", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_5" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_5"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_5" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; jQuery( document ).trigger( 'gform_post_render', [5, 1] ); gform.utils.trigger( { event: 'gform/postRender', native: false, data: { formId: 5, currentPage: 1 } } ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } ); /* ]]> */ </script> </body> </html>

CINXE.COM

Let’s do something life-changing together